Browsing Tag
wet AMD
9 posts
Can Lilly’s milestone-heavy deal for Adverum reshape how Big Pharma acquires gene therapy platforms?
Lilly’s $12.47-per-share buyout of Adverum Biotechnologies puts milestone CVRs at the center of biotech M&A. But can this deal model truly balance risk and reward?
Is Ocular Therapeutix the next big biotech buyout? Takeover rumors spark investor frenzy
Ocular Therapeutix stock jumps on takeover rumors. Find out what analysts are saying, and why Axpaxl could make it biotech’s next big M&A target.
Vabysmo shows 4-year durability in wet AMD and 60% lesion clearance in PCV: What the new Genentech data reveals
Genentech’s Vabysmo shows four years of vision durability in AMD and strong lesion control in PCV—see what’s next for this bispecific breakthrough.
4D Molecular Therapeutics strengthens cash position, eyes Phase 3 success for 4D-150
4D Molecular Therapeutics (4DMT) has announced its full-year 2024 financial results, highlighting key advancements in its late-stage clinical…
Outlook Therapeutics trims workforce by 23% to fund Lytenava launch
Outlook Therapeutics, a biopharmaceutical company specialising in retina disease treatments, has announced a 23% workforce reduction as part…
Genentech announces reintroduction of Susvimo for Wet AMD treatment in US
Genentech, a key member of the Roche Group, has officially announced the reintroduction of Susvimo (ranibizumab injection) 100…
Kodiak Sciences’ KSI-301 fails to meet primary endpoint in wet AMD trial
Kodiak Sciences said that its antibody biopolymer conjugate KSI-301 failed to meet the primary endpoint in a phase…
KSI-301 phase 1b trial : Kodiak Sciences reports new safety, efficacy, and durability data
KSI-301 phase 1b trial : Kodiak Sciences said that its ongoing phase 1b clinical trial of its intravitreal…
Novartis bags Beovu FDA approval for wet AMD
Beovu FDA approval for wet AMD : Swiss pharma giant Novartis has been given approval from the US…